Andrei Shustov
Seagen Inc. · Seattle Cancer Care Alliance, Seattle, WA, USA · Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrei Shustov as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:39 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05244473 · A Safety Study of Brentuximab Vedotin in Participants With HIVSeagen Inc. · withdrawn · Human Immunodeficiency Virus · study director
- N/ANCT03964480 · Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.Associazione Angela Serra per la ricerca sul cancro · recruiting · Peripheral T-Cell Lymphoma · principal investigator
- Ph1/Ph2NCT02729961 · Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaUniversity of Washington · withdrawn · Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma · principal investigator
- Ph2NCT00958074 · Vorinostat in Patients With Primary Cutaneous T-Cell LymphomaUniversity of Washington · terminated · Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II, Cutaneous T-cell Lymphoma Stage III · principal investigator
- Ph2NCT00865969 · Belinostat in Relapsed or Refractory Peripheral T-Cell LymphomaSpectrum Pharmaceuticals, Inc · completed · Peripheral T-cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT02729961
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:39 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- 988 citationsRCR 28.2
- Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.J Clin Oncol · 2012813 citationsRCR 21.7
- 623 citationsRCR 24.0
- Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.J Clin Oncol · 2012566 citationsRCR 14.1
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.Lancet Oncol · 2018563 citationsRCR 19.4
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.J Clin Oncol · 2011541 citationsRCR 14.1
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.J Clin Oncol · 2015472 citationsRCR 13.0
- 240 citationsRCR 16.7
- Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.J Clin Oncol · 2020210 citationsRCR 9.0
- 202 citationsRCR 6.8